News

LRF Scientific Advisory Board (SAB) member and grantee Michael Williams, MD, of the University of Virginia School of Medicine, sees lymphoma research as having a ripple effect. A lymphoma researcher has a much larger impact on the lives of those touched by this disease.

Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provided a critical forum for leading hematologists/ oncologists to present their findings to over 20,000 of their peers.

Allogeneic hematopoietic stem cell transplant (allo-HSCT) may be a successful curative treatment for T-cell patients with poor survival and/or limited treatment options, according to a retrospective study led by LRF grantee Neha Mehta-Shah, MD of the Washington University School of Medicine in St. Louis.

Myelodysplastic Syndromes (MDS), also known as “bone marrow failure disorder,” are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.

Researchers in BRUIN trial reveals promising data on BTK inhibitor in treatment for CLL, MCL and WM

Odronextamab, a bispecific antibody targeting CD20 and CD3, led to response rates as high as 90 percent in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who underwent chimeric antigen receptor (CAR) T cell therapy, according to early trials results.

A time-limited, frontline combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) shows to mobilize and clear CLL leading to deep responses for patients who achieved undetectable minimal residual disease (MRD) status, according to results from the CAPTIVATE study.

Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, appeared an effective frontline (initial) treatment for high-risk large B-cell lymphomas.